Reset
Showing 20 of 21 academic articles

CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase

Jing Yang, Pengfei Li, Pengfei Li, Pengfei Li et al. • Frontiers in Immunology (2022)

ObjectiveExtranodal natural killer/T cell lymphoma (NKTCL) is an aggressive EBV-related lymphoma, originating from NK cells or T cells. Previous study demonstrated that CD56 negative NKTCL should be recognized as a distinct subtype. In this...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2022.829366

Evaluating key predictors of breast cancer through survival: a comparison of AFT frailty models with LASSO, ridge, and elastic net regularization

Senyefia Bosson-Amedenu, Emmanuel Ayitey, Francis Ayiah-Mensah, Luyton Asare • BMC Cancer (2025)

Abstract Background Frailty models are extensively utilized in survival analysis to address unobserved heterogeneity among individuals. However, selecting the most robust model for survival prediction, especially in the context of high-dime...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12885-025-14040-z

Program-Based Lung Cancer Care: A Prospective Observational Tumor Registry Linkage Study

Wei Liao, PhD, Meredith Ray, PhD, Carrie Fehnel, BBA, Jordan Goss, MA et al. • JTO Clinical and Research Reports (2024)

Introduction: Low-dose computed tomography screening (LDCT) and lung nodule programs (LNP) promote early lung cancer detection, improve survival; Multidisciplinary Care Programs (MDC) promote guideline-concordant care. The impact of such pr...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.jtocrr.2023.100629

Identification and Validation of PLOD2 as an Adverse Prognostic Biomarker for Oral Squamous Cell Carcinoma

Yawei Sun, Shuai Wang, Xingwei Zhang, Zhuhao Wu et al. • Biomolecules (2021)

Background: Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), a key enzyme that catalyzes the hydroxylation of lysine, plays a crucial role in the progression of several solid tumors. However, its spatial expression profile and pr...

DOAJ Open Access (DOAJ) DOI: 10.3390/biom11121842

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer

Xuanzhao Chen, Zeyan Li, Meihua Liang, Ziyang Zhang et al. • World Journal of Surgical Oncology (2023)

Abstract Background Triple-negative breast cancer (TNBC) is the most heterogenous and aggressive subtype of breast cancer. Chemotherapy remains the standard treatment option for patients with TNBC owing to the unavailability of acceptable t...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12957-023-03078-7

Poster 58. Preoperative Corticosteroid Injection History Does Not Influence Meniscal Allograft Transplantation Survivorship or Failure Rates

Vishal Sundaram, Isabella Jazrawi BA, Rushani K. Cameron MS, Cody Perskin et al. • Orthopaedic Journal of Sports Medicine (2026)

Objective: Meniscal allograft transplantation (MAT) is a joint-preserving option for patients with symptomatic meniscal deficiency unresponsive to nonoperative care. By restoring tibiofemoral load transmission, MAT can relieve pain, improve...

DOAJ Open Access (DOAJ) DOI: 10.1177/2325967126S00369

Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial

Yanshang Wang, Xiaoping Wei • BMJ Open (2026)

Introduction Electronic patient-reported outcome (ePROs)-based symptom monitoring benefits health-related quality of life (HRQoL) in various cancers. However, despite the high disease and economic burden of hepatocellular carcinoma (HCC) an...

DOAJ Open Access (DOAJ) DOI: 10.1136/bmjopen-2026-116199

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation

Liya Ma, Bin Liang, Huixian Hu, Wenli Yang et al. • Frontiers in Oncology (2022)

The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS...

DOAJ Open Access (DOAJ) DOI: 10.3389/fonc.2022.905490

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer (2024)

Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...

DOAJ Open Access (DOAJ) DOI: 10.1136/jitc-2023-008450

Optimization of GDMT for patients with heart failure and reduced ejection fraction: can physiological and biological barriers explain the gaps in adherence to heart failure guidelines?

Marilyne Jarjour, Anique Ducharme • Drugs in Context (2023)

Heart failure is a growing epidemic with high mortality rates and recurrent hospital admissions that creates a burden on affected individuals, their caregivers and the whole healthcare system. Throughout the years, many randomized trials ha...

DOAJ Open Access (DOAJ) DOI: 10.7573/dic.2023-5-6

Outcomes of primary gastrointestinal diffuse large B cell lymphoma in the rituximab era

Luyao Zhang, Jianwen Zhou, Yanyan Sun, Yaodong Zhang et al. • Discover Oncology (2026)

Abstract Background Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) constitutes 30%-40% of primary extranodal lymphomas. While rituximab has significantly improved survival in nodal DLBCL, its impact on the prognosis of P...

DOAJ Open Access (DOAJ) DOI: 10.1007/s12672-026-05022-z

Tumor probability mapping of fluorescence intensity during image-guided surgery of head and neck cancer

Akhilesh M Wodeyar, Sherin James, Benjamin B. Kasten, Nicolaus D. Knight et al. • Scientific Reports (2026)

Abstract Achieving negative surgical margins remains a critical determinant of local recurrence and survival in head and neck cancer (HNC) surgery. Current intraoperative margin assessment techniques, including frozen section analysis, suff...

DOAJ Open Access (DOAJ) DOI: 10.1038/s41598-026-56078-4

Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition

Susheel Kumar Nethi, Venugopal Gunda, Nagabhishek Sirpu Natesh, Brianna M. White et al. • iScience (2025)

Summary: Pancreatic cancer (PC) exhibits profound metabolic adaptations that support tumor progression, survival, and therapy resistance. Hypoxia-inducible factor-1α (HIF-1α) is a key regulator of these processes, promoting metabolic reprog...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.isci.2025.114088

Integrative multiomics analysis of platelet-related genes unveils molecular subtypes and prognostic signatures in acute myeloid leukemia

Fangmin Zhong, Fangyi Yao, Zihao Wang, Bo Huang et al. • npj Precision Oncology (2025)

Abstract Acute myeloid leukemia (AML) remains challenging due to molecular heterogeneity and limited prognostic models integrating tumor microenvironment dynamics. While thrombocytopenia correlates with poor outcomes, the roles of platelet-...

DOAJ Open Access (DOAJ) DOI: 10.1038/s41698-025-01137-8

A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients

Claire Tardiveau, Claire Tardiveau, Guillaume Monneret, Guillaume Monneret et al. • Frontiers in Immunology (2022)

Immune responses affiliated with COVID-19 severity have been characterized and associated with deleterious outcomes. These approaches were mainly based on research tools not usable in routine clinical practice at the bedside. We observed th...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2022.1022750

Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma

Caroline W. Grant, Jerry Li, Swan Lin, Dana Nickens et al. • Clinical and Translational Science (2025)

ABSTRACT Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five‐year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine and accelerate drug developmen...

DOAJ Open Access (DOAJ) DOI: 10.1111/cts.70348